Lundbeck spotlights Phase III MASCOT trial baseline data for amlenetug in multiple system atrophy at MDS 2026

• Lundbeck flagged new movement-disorders readouts slated for MDS 2026 in Seoul on Oct. 4-8.
• A late-breaking Phase III MASCOT presentation will profile enrolled patients in the ongoing amlenetug trial in multiple system atrophy.
• The study is testing amlenetug against placebo over 72 weeks; top-line efficacy and safety results are expected in Q3 2027.
• An 18-week Phase Ib update for Lu AF28996 in advanced Parkinson’s disease will outline safety, tolerability, and signals of clinical effect.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief via Cision (Ref. ID: 202610020200BITN____UKPR__EN_20261001-BIT-8128-0) on October 02, 2026, and is solely responsible for the information contained therein.